Table 1.
Distribution of Cases and Controls
| Overall (N = 1023) | Cases (n = 525) | Controls (n = 498) | |
|---|---|---|---|
| Age | |||
| 18–29 y | 395 (38.6) | 200 (38.1) | 195 (39.2) |
| 30–49 y | 363 (35.5) | 188 (35.8) | 175 (35.1) |
| 50–64 y | 192 (18.8) | 100 (19.0) | 92 (18.5) |
| ≥65 y | 73 (7.1) | 37 (7.0) | 36 (7.2) |
| Region | |||
| Predominantly urban regions | |||
| San Francisco Bay area | 129 (12.6) | 66 (12.6) | 63 (12.7) |
| Greater Los Angeles area | 91 (8.9) | 48 (9.1) | 43 (8.6) |
| Greater Sacramento area | 115 (11.2) | 58 (11.0) | 57 (11.4) |
| San Diego and southern border | 110 (10.8) | 54 (10.3) | 56 (11.2) |
| Predominantly rural regions | |||
| Central Coast | 140 (13.7) | 74 (14.1) | 66 (13.3) |
| Northern Sacramento Valley | 116 (11.3) | 60 (11.4) | 56 (11.2) |
| San Joaquin Valley | 106 (10.4) | 54 (10.3) | 52 (10.4) |
| Northwestern California | 108 (10.6) | 55 (10.5) | 53 (10.6) |
| Sierras region | 108 (10.6) | 56 (10.7) | 52 (10.4) |
| Sex | |||
| Male | 519 (50.7) | 264 (50.3) | 255 (51.2) |
| Female | 504 (49.3) | 261 (49.7) | 243 (48.8) |
| Household income | |||
| Under $50 000 | 272 (26.6) | 153 (29.1) | 119 (23.9) |
| $50 000 to $100 000 | 220 (21.5) | 113 (21.5) | 107 (21.5) |
| $100 000 to $150 000 | 121 (11.8) | 45 (8.6) | 76 (15.3) |
| Over $150 000 | 135 (13.2) | 64 (12.2) | 71 (14.3) |
| Refused | 154 (15.1) | 86 (16.4) | 68 (13.7) |
| Not sure | 121 (11.8) | 64 (12.2) | 57 (11.4) |
| Race/ethnicity | |||
| White | 444 (43.4) | 217 (41.4) | 227 (45.6) |
| Hispanic | 286 (28.0) | 160 (30.5) | 126 (25.3) |
| Asian | 115 (11.3) | 58 (11.1) | 57 (11.4) |
| Black | 47 (4.6) | 30 (5.7) | 17 (3.4) |
| More than 1 race | 89 (8.7) | 36 (6.9) | 53 (10.6) |
| Native American | 16 (1.6) | 11 (2.1) | 5 (1.0) |
| Native Hawaiian | 10 (1.0) | 4 (0.8) | 6 (1.2) |
| Refused | 15 (1.5) | 8 (1.5) | 7 (1.4) |
| Vaccination | |||
| Unvaccinated | 767 (75.0) | 454 (86.5) | 313 (62.9) |
| Incompletely vaccinated | 150 (14.7) | 51 (9.7) | 99 (19.9) |
| Fully vaccinateda | 106 (10.4) | 20 (3.8) | 86 (17.3) |
Data are presented as n (%).
aAn individual was considered “fully vaccinated” >14 days after 2 doses of Pfizer/BioNTech BNT162b2 or Moderna mRNA-1273 and “incompletely vaccinated” if they received only 1 dose or 2 doses <14 days after the second dose